WorldPingAl Jazeera
Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread
Moderna's mRNA vaccine Intismeran shows promise, reducing melanoma recurrence and spread in late-stage trials.
Brief by WorldPing · Original reporting by Al Jazeera
Phys.org
Modern consumption patterns traced back to WWII mobilization
WorldPingResearch in the International Journal of Sustainable Development has examined eight nations involved in World War II, both Allied and Axis countries, and shows how that period of history helped set societies on the path to the resource-intensive mode…
This is a short WorldPing brief. The full report was published by Phys.org.
Read the full report at Phys.orgRelated news
CNBC World
Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soar
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
Brief by WorldPing · Original reporting by CNBC World
WorldPingFortune
Moderna’s and Merck’s personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring
The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients.
Brief by WorldPing · Original reporting by Fortune
WorldPingDecrypt
Moderna Stock Doubles on Cancer Breakthrough: Here’s What It Means
A Phase 3 win against the standard of care sent the biotech's shares up 131% and left short sellers down $4.8 billion.
Brief by WorldPing · Original reporting by Decrypt